File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: 2018 update of the APLAR recommendations for treatment of rheumatoid arthritis

Title2018 update of the APLAR recommendations for treatment of rheumatoid arthritis
Authors
Keywordsbiological disease‐modifying antirheumatic drugs
disease‐modifying antirheumatic drugs
DMARDs
rheumatoid arthritis
targeted therapy
Issue Date2019
PublisherWiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwell-synergy.com/loi/ijrd
Citation
International Journal of Rheumatic Diseases, 2019, v. 22 n. 3, p. 357-375 How to Cite?
AbstractAim: To update recommendations based on current best evidence concerning the treatment of rheumatoid arthritis (RA), focusing particularly on the role of targeted therapies, to inform clinicians on new developments that will impact their current practice. Materials and methods: A search of relevant literature from 2014 to 2016 concerning targeted therapies in RA was conducted. The RA Update Working Group evaluated the evidence and proposed updated recommendations using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach, to describe the quality of evidence and strength of recommendations. Recommendations were finalized through consensus using the Delphi technique. Results: This update provides 16 RA treatment recommendations based on current best evidence and expert clinical opinion. Recommendations 1‐3 deal with the use of conventional synthetic disease‐modifying antirheumatic drugs. The next three recommendations (4‐6) cover the need for screening and management of infections and comorbid conditions prior to starting targeted therapy, while the following seven recommendations focus on use of these agents. We address choice of targeted therapy, switch, tapering and discontinuation. The last three recommendations elaborate on targeted therapy for RA in special situations such as pregnancy, cancer, and major surgery. Conclusion: Rheumatoid arthritis remains a significant health problem in the Asia‐Pacific region. Patients with RA can benefit from the availability of effective targeted therapies, and these updated recommendations provide clinicians with guidance on their use.
DescriptionLink to Free access
Persistent Identifierhttp://hdl.handle.net/10722/273941
ISSN
2017 Impact Factor: 2.423
2015 SCImago Journal Rankings: 0.536

 

DC FieldValueLanguage
dc.contributor.authorLau, CS-
dc.contributor.authorChia, F-
dc.contributor.authorDans, L-
dc.contributor.authorHarrison, A-
dc.contributor.authorHsieh, TY-
dc.contributor.authorJain, R-
dc.contributor.authorJung, SM-
dc.contributor.authorKishimoto, M-
dc.contributor.authorKumar, A-
dc.contributor.authorLeong, KP-
dc.contributor.authorLi, Z-
dc.contributor.authorLichauco, JJ-
dc.contributor.authorLouthrenoo, W-
dc.contributor.authorLuo, SF-
dc.contributor.authorMu, R-
dc.contributor.authorNash, P-
dc.contributor.authorNg, CT-
dc.contributor.authorSuryana, B-
dc.contributor.authorWijaya, LK-
dc.contributor.authorYeap, SS-
dc.date.accessioned2019-08-18T14:51:49Z-
dc.date.available2019-08-18T14:51:49Z-
dc.date.issued2019-
dc.identifier.citationInternational Journal of Rheumatic Diseases, 2019, v. 22 n. 3, p. 357-375-
dc.identifier.issn1756-1841-
dc.identifier.urihttp://hdl.handle.net/10722/273941-
dc.descriptionLink to Free access-
dc.description.abstractAim: To update recommendations based on current best evidence concerning the treatment of rheumatoid arthritis (RA), focusing particularly on the role of targeted therapies, to inform clinicians on new developments that will impact their current practice. Materials and methods: A search of relevant literature from 2014 to 2016 concerning targeted therapies in RA was conducted. The RA Update Working Group evaluated the evidence and proposed updated recommendations using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach, to describe the quality of evidence and strength of recommendations. Recommendations were finalized through consensus using the Delphi technique. Results: This update provides 16 RA treatment recommendations based on current best evidence and expert clinical opinion. Recommendations 1‐3 deal with the use of conventional synthetic disease‐modifying antirheumatic drugs. The next three recommendations (4‐6) cover the need for screening and management of infections and comorbid conditions prior to starting targeted therapy, while the following seven recommendations focus on use of these agents. We address choice of targeted therapy, switch, tapering and discontinuation. The last three recommendations elaborate on targeted therapy for RA in special situations such as pregnancy, cancer, and major surgery. Conclusion: Rheumatoid arthritis remains a significant health problem in the Asia‐Pacific region. Patients with RA can benefit from the availability of effective targeted therapies, and these updated recommendations provide clinicians with guidance on their use.-
dc.languageeng-
dc.publisherWiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwell-synergy.com/loi/ijrd-
dc.relation.ispartofInternational Journal of Rheumatic Diseases-
dc.rightsPreprint This is the pre-peer reviewed version of the following article: [FULL CITE], which has been published in final form at [Link to final article using the DOI]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. Postprint This is the peer reviewed version of the following article: [FULL CITE], which has been published in final form at [Link to final article using the DOI]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.-
dc.subjectbiological disease‐modifying antirheumatic drugs-
dc.subjectdisease‐modifying antirheumatic drugs-
dc.subjectDMARDs-
dc.subjectrheumatoid arthritis-
dc.subjecttargeted therapy-
dc.title2018 update of the APLAR recommendations for treatment of rheumatoid arthritis-
dc.typeArticle-
dc.identifier.emailLau, CS: cslau@hku.hk-
dc.identifier.authorityLau, CS=rp01348-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/1756-185X.13513-
dc.identifier.pmid30809944-
dc.identifier.scopuseid_2-s2.0-85062348735-
dc.identifier.hkuros301861-
dc.identifier.volume22-
dc.identifier.issue3-
dc.identifier.spage357-
dc.identifier.epage375-
dc.publisher.placeAustralia-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats